Management of chronic HBV-HDV patients chronic HBV-HDV infection: A review on new management options

被引：4

作者：

Buti, Maria ^{[1
,2
,3
]}

Gonzalez, Alexia ^{[4
]}

Riveiro-Barciela, Mar ^{[1
,2
,3
]}

Bourliere, Marc ^{[4
,5
]}

机构：

[1] Hosp Univ ValldHebron, ValldHebron Barcelona Hosp Campus, Internal Med Dept, Liver Unit, Barcelona, Spain

[2] Univ Autonoma Barcelona, Dept Med, Barcelona, Spain

[3] Inst Carlos III, CIBERehd, Barcelona 08036, Spain

[4] Hop St Joseph, Liver Unit, Marseille, France

[5] Aix Marseille Univ, Sci Econ & Sociales Sante & Traitement Informat Me, ISSPAM, Inserm,IRD,SESSTIM, Marseille, France

来源：

UNITED EUROPEAN GASTROENTEROLOGY JOURNAL | 2024年 / 12卷 / 02期

关键词：

Buleviritide; chronic HBV-HDV infection; hepatitis B virus; hepatitis D virus; interferon alpha; lonafarnib; CHRONIC HEPATITIS-D; CHRONIC DELTA-HEPATITIS; D VIRUS-INFECTION; BULEVIRTIDE MONOTHERAPY; PEGINTERFERON ALPHA-2A; MG; COMPENSATED CIRRHOSIS; B-VIRUS; EFFICACY; SAFETY;

D O I：

10.1002/ueg2.12494

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Hepatitis D virus was first described by Mario Rizzeto in 1977, and it is considered chronic viral hepatitis with the poorest prognosis. Despite its discovery almost 50 years ago, progress in its diagnosis and treatment has been scarce until recent years. The approval of bulevirtide has shed some light for patients with Chronic Hepatitis D, although important gaps regarding its use in therapy as well as about the epidemiology and diagnosis of the disease need to be addressed. image

引用

页码：210 / 218

页数：9

共 54 条

[1]

Anolli MP., 2023, J HEPATOL

[2]

[Anonymous], 2023, J HEPATOL

[3]

Asselah T, 2021, J HEPATOL, V75, pS291

[4] Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139-Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection [J].

Bazinet, Michel ;

Pantea, Victor ;

Cebotarescu, Valentin ;

Cojuhari, Lilia ;

Jimbei, Pavlina ;

Anderson, Mark ;

Gersch, Jeff ;

Holzmayer, Vera ;

Elsner, Carina ;

Krawczyk, Adalbert ;

Kuhns, Mary C. ;

Cloherty, Gavin ;

Dittmer, Ulf ;

Vaillant, Andrew .

HEPATOLOGY COMMUNICATIONS, 2021, 5 (02) :189-202

[5] Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial [J].

Bazinet, Michel ;

Pantea, Victor ;

Cebotarescu, Valentin ;

Cojuhari, Lilia ;

Jimbei, Pavlina ;

Albrecht, Jeffrey ;

Schmid, Peter ;

Le Gal, Frederic ;

Gordien, Emmanuel ;

Krawczyk, Adalbert ;

Mijocevic, Hrvoje ;

Karimzadeh, Hadi ;

Roggendorf, Michael ;

Vaillant, Andrew .

LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (12) :877-889

[6] Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study [J].

Bogomolov, Pavel ;

Alexandrov, Alexander ;

Voronkova, Natalia ;

Macievich, Maria ;

Kokina, Ksenia ;

Petrachenkova, Maria ;

Lehr, Thorsten ;

Lempp, Florian A. ;

Wedemeyer, Heiner ;

Haag, Mathias ;

Schwab, Matthias ;

Haefeli, Walter E. ;

Blank, Antje ;

Urban, Stephan .

JOURNAL OF HEPATOLOGY, 2016, 65 (03) :490-498

[7]

Bourliere M, 2023, J HEPATOL, V78, pS1150

[8] The hepatitis D virus in Italy. A vanishing infection, not yet a vanished disease [J].

Caviglia, Gian Paolo ;

Martini, Silvia ;

Ciancio, Alessia ;

Niro, Grazia Anna ;

Olivero, Antonella ;

Fontana, Rossana ;

Tandoi, Francesco ;

Rosso, Chiara ;

Romagnoli, Renato ;

Saracco, Giorgio Maria ;

Smedile, Antonina ;

Rizzetto, Mario .

JOURNAL OF ADVANCED RESEARCH, 2021, 33 :183-187

[9] Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis [J].

Chen, Hai-Yan ;

Shen, Dan-Ting ;

Ji, Dong-Ze ;

Han, Pei-Chun ;

Zhang, Wei-Ming ;

Ma, Jian-Feng ;

Chen, Wen-Sen ;

Goyal, Hemant ;

Pan, Shiyang ;

Xu, Hua-Guo .

GUT, 2019, 68 (03) :512-521

[10]

de Lédinghen V, 2023, J HEPATOL, V78, pS1160

← 1 2 3 4 5 6 →